Education
About Us
Working with TipRanks
Follow Us
Finch Therapeutics Group (FNCH)
OTHER OTC:FNCH
RESEARCH TOOLSreports
FNCH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.15 - $16.00
Previous CloseN/A
Volume338.00
Average Volume (3M)1.91K
Market Cap
$19.91M
Enterprise Value$12.98M
Total Cash (Recent Filing)$16.04M
Total Debt (Recent Filing)$28.99M
Price to Earnings (P/E)―
Beta1.70
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.82
Shares Outstanding1,605,763
10 Day Avg. Volume462
30 Day Avg. Volume1,914
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue4.56
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda-0.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Finch Therapeutics Group News
FNCH FAQ
What was Finch Therapeutics Group’s price range in the past 12 months?
Finch Therapeutics Group lowest stock price was $10.15 and its highest was $16.00 in the past 12 months.
What is Finch Therapeutics Group’s market cap?
Finch Therapeutics Group’s market cap is $19.91M.
When is Finch Therapeutics Group’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Finch Therapeutics Group’s earnings last quarter?
Finch Therapeutics Group released its earnings results on Mar 28, 2024. The company reported -$1.894 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.894.
Is Finch Therapeutics Group overvalued?
According to Wall Street analysts Finch Therapeutics Group’s price is currently Overvalued.
Does Finch Therapeutics Group pay dividends?
Finch Therapeutics Group does not currently pay dividends.
What is Finch Therapeutics Group’s EPS estimate?
Finch Therapeutics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Finch Therapeutics Group have?
Finch Therapeutics Group has 1,605,763 shares outstanding.
What happened to Finch Therapeutics Group’s price movement after its last earnings report?
Finch Therapeutics Group reported an EPS of -$1.894 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.245%.
Which hedge fund is a major shareholder of Finch Therapeutics Group?
Currently, no hedge funds are holding shares in FNCH
Company Description
Finch Therapeutics Group
Finch Therapeutics Group (FNCH) is a clinical-stage biopharmaceutical company focused on developing novel microbiome therapies. The company operates in the biotechnology sector and is dedicated to harnessing the human microbiome to develop innovative treatments for a range of diseases, with a particular emphasis on gastrointestinal conditions, including recurrent Clostridium difficile infection (CDI). Finch Therapeutics employs a unique platform that leverages both its human-first discovery and machine learning capabilities to identify and develop microbiome-based therapies.
Technical Analysis
Ownership Overview
2.63% Insiders
0.47% Mutual Funds
1.32% Other Institutional Investors
98.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---